Skip to content

Intuitive Surgical Stock (NASDAQ: ISRG)

Nasdaq Healthcare Medical Instruments & Supplies

$440.75 +$3.88 (+0.89%)
At close: 3 Nov 2026

ISRG Stock Chart

Key Statistics

Market Cap
$155.71bn
P/E Ratio (TTM)
53.30
EPS (TTM)
$8.27
Dividend Yield
0.00%
52-Week Range
$328.57 – $603.88
Day Range
$434.05 – $443.58
Volume
1,716,612
Avg. Volume (50 Days)
2,316,985
Beta
1.44
50-Day Average
$404.05
200-Day Average
$432.07
Shares Outstanding
353.28m

About Intuitive Surgical

Intuitive Surgical makes robotic-assisted systems for minimally invasive surgery, selling to hospitals both in its home market and abroad. Its best-known product is the da Vinci Surgical System, which lets surgeons operate through small incisions. The Ion system takes the same approach beyond surgery into diagnosis, guiding minimally invasive lung biopsies.

The group's offering has three parts. Systems, such as da Vinci and Ion, are sold through its own capital and clinical sales teams. Alongside them it supplies stapling, energy and core instruments for multi-port da Vinci systems, plus training pathways for surgeons. Services cover installation, repair, maintenance, round-the-clock technical support and system health monitoring, with digital tools that give hospitals performance insights. The company dates from 1995.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Listed
NASDAQ: ISRG
Listed Since
13 Jun 2000
Headquarters
Sunnyvale, CA
Country
USA
Employees
17,021
Year End
December
Website
intuitive.com

Earnings

Last Results
20 Oct 2026
Beat estimates
EPS Est. (FY 2026)
$11.25
27 analysts
Last EPS
$3.00
EPS – Reported vs Estimated
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26

Estimated EPS Reported EPS

Quarter Ended Estimate Reported EPS Surprise Reported
Sep 2026 $2.13 $3.00 +40.85% 20 Oct 2026
Jun 2026 $2.02 $2.80 +38.61% 16 Jul 2026
Mar 2026 $2.11 $2.50 +18.48% 21 Apr 2026
Dec 2025 $2.27 $2.53 +11.45% 22 Jan 2026
Sep 2025 $1.99 $2.40 +20.60% 21 Oct 2025
Jun 2025 $1.92 $2.19 +14.06% 22 Jul 2025
Mar 2025 $1.73 $1.81 +4.62% 22 Apr 2025
Dec 2024 $1.79 $2.21 +23.46% 23 Jan 2025

Ownership

Institutions
91.30%
Insiders
0.52%
Short Interest
2.08%
Free Float
344.60m
Institutional Holder Shares % Owned Change
BlackRock Inc 30.02m 8.45% −0.17%
Vanguard Capital Management, LLC 23.13m 6.51% +0.22%
State Street Corp 16.06m 4.52% +1.36%
Amvescap Plc. 11.84m 3.33% +5.84%
T. Rowe Price Associates, Inc. 11.26m 3.17% −10.09%
Geode Capital Management, LLC 8.53m 2.40% +0.80%
Capital World Investors 7.74m 2.18% −3.79%
Vanguard Portfolio Management, LLC 7.24m 2.04% +0.13%
Morgan Stanley - Brokerage Accounts 6.56m 1.85% +8.29%
NORGES BANK 4.95m 1.40% −1.78%

Our Analysis

Intuitive Surgical stock (NASDAQ: ISRG) shares have increased 18.72% in the last 12 months and shareholders have seen the shares decline by -2.80% since the start of the year.

In spite of the recent upside, the mixed financial performance can be linked to executive leadership changes, analyst sentiments, and insider trading activities paint a complex picture, demanding a closer examination of the company’s prospects and potential challenges.

The past year has been marked by a mixture of positive milestones and emerging concerns for Intuitive Surgical. The company’s first-quarter 2025 results, reported in April, showcased impressive financial performance. Revenue surged 19.2% year-over-year to $2.25 billion, driven by a significant increase in da Vinci surgical procedures and an expanding installed base. Non-GAAP earnings per share (EPS) reached $1.81, exceeding analyst expectations by 4.4%.

This strong performance underscores the continued demand for robotic-assisted surgery and Intuitive Surgical’s ability to capitalize on this trend. Procedure growth, a key metric for the company, demonstrates the increasing adoption of the da Vinci system across various surgical specialties.

Intuitive Surgical Share Price Targets

Analysts have set a 12-month price target for Intuitive Surgical with an average expectation of $575.49, ranging from a high of $675.00 to a low of $350.00.

The current consensus average target suggests a potential increase of 12.98% from the most recent trading price.

Our View: You would be wise to consider the views of the analyst community in conjunction with the fundamentals surrounding the company to properly determine a value for the stock that you feel is appropriate.

At the upper end of analysts estimates it would be easy to get carried away with the potential gains on show, but the flipside is that these targets can shift within the blink of an eye and that the view of analysts is very dynamic.

If you are considering swing trading, or day trading Intuitive Surgical shares that is a separate consideration, but for those planning for the long haul, fundamental analysis is king.

Intuitive Surgical – The Basics Driving The Business

Intuitive Surgical is a pioneer and global leader in robotic-assisted surgery. The company’s innovative da Vinci surgical system has revolutionized minimally invasive procedures, offering surgeons enhanced precision, dexterity, and control, ultimately leading to improved patient outcomes. As a result, Intuitive Surgical has enjoyed substantial growth and market dominance over the past two decades.

Intuitive Surgical designs, manufactures, and markets the da Vinci surgical systems and related instruments and accessories. These systems enable surgeons to perform complex procedures through small incisions, reducing trauma, blood loss, and recovery time compared to traditional open surgery.

The company’s business model is multifaceted, generating revenue from system sales, recurring instrument and accessory sales (driven by procedure volume), and service contracts. This recurring revenue stream provides a degree of stability and predictability, attractive to investors.

Intuitive Surgical’s global presence is significant, with systems installed in hospitals worldwide, although the United States remains its largest market. The company continually invests in research and development to enhance its existing technology and expand its portfolio of surgical applications.

Analyst Team
Analyst Team
Team Member

The AskTraders Analyst Team features experts in technical and fundamental analysis, as well as traders specializing in stocks, forex, and cryptocurrency.

Analyst Rating

  • Strong Sell
  • Sell
  • Hold
  • Buy
  • Strong Buy
Consensus Rating
Buy (4.24/5)
Average Price Target
$482.63
Upside from Last Close
+9.5%
Number of Analysts
34

Financials

Revenue (TTM)
$11.58bn
Net Margin
25.54%
Operating Margin
33.29%
Return on Equity
17.93%
Return on Assets
11.85%
Forward P/E
35.97
PEG Ratio
2.02
Price to Sales
13.45
Price to Book
9.65
Book Value per Share
$46.12
Debt to Equity
0.02
Current Ratio
4.87
Revenue (Annual)
Dec 22
Dec 23
Dec 24
Dec 25
USD (billions) Dec 2025 Dec 2024 Dec 2023 Dec 2022
Revenue 10.06 8.35 7.12 6.22
Net Income 2.86 2.32 1.80 1.32
Net Margin 28.4% 27.8% 25.2% 21.3%
Operating Cash Flow 3.03 2.42 1.81 1.49
Debt to Equity 0.02 0.01 0.01 0.01

Latest News & Analysis

View more

Figures as of 4 Nov 2026.

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.